In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 51 to 100 of 217

TitleTypeExpected publication date
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]Technology appraisal guidanceTBC
Deuruxolitinib for treating severe alopecia areata ID6597Technology appraisal guidance
Deutetrabenazine for treating tardive dyskinesia ID6550Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726Technology appraisal guidanceTBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidanceTBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]Highly specialised technologyTBC
Dupilumab for treating bullous pemphigoid [ID6479]Technology appraisal guidanceTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]Technology appraisal guidanceTBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]Technology appraisal guidanceTBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]Technology appraisal guidance
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Technology appraisal guidanceTBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Technology appraisal guidanceTBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Technology appraisal guidance
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidanceTBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]Technology appraisal guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]Technology appraisal guidanceTBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]Technology appraisal guidanceTBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidanceTBC
Filgotinib for treating axial spondyloarthritis ID6594Technology appraisal guidanceTBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidanceTBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]Technology appraisal guidanceTBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576Technology appraisal guidanceTBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidanceTBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]Technology appraisal guidanceTBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidanceTBC
Ianalumab for treating active Sjogren's syndrome [ID6634]Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]Technology appraisal guidanceTBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579Technology appraisal guidanceTBC
ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)Technology appraisal guidance
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]Technology appraisal guidanceTBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All